Initial Section 16 Filing: BBOT Director Declares No Beneficial Ownership

Rhea-AI Filing Summary

Form 3 initial statement: Jake Bauer filed an initial Section 16 Form 3 reporting his relationship with BridgeBio Oncology Therapeutics (ticker BBOT) as a director. The filing states that no securities are beneficially owned by the reporting person and includes an Exhibit 24 power of attorney authorizing an attorney-in-fact to sign the form.

Insights

Corporate Governance Expert

TL;DR: A director filed an initial ownership report and declared no beneficial holdings, reducing immediate insider-transaction disclosure concerns.

The Form 3 documents an initial Section 16 filing by a company director who reports no beneficial ownership of the issuer's securities and attaches a Power of Attorney. That means there are currently no insider holdings to be tracked for trading activity in subsequent Forms 4 or 5. From a governance perspective, the filing is routine and raises no immediate reporting red flags.

Securities Compliance Analyst

TL;DR: Routine compliance filing; absence of holdings simplifies future Section 16 monitoring but offers limited investor insight.

The submission fulfills Section 16 initial-reporting obligations by identifying the reporting person and their status as a director. The declaration of no securities beneficially owned eliminates the need to reconcile existing positions, but also provides no material information about potential insider alignment with shareholders. The included Power of Attorney indicates the form was executed via an authorized representative.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bauer Jake

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/11/2025

3. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Aaron Chan, Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 3 for BridgeBio Oncology Therapeutics (BBOT)?

The Form 3 was filed on behalf of Jake Bauer, who is identified as a director of BridgeBio Oncology Therapeutics (ticker BBOT).

Does the Form 3 report any securities beneficially owned by the reporting person?

No. The filing explicitly states no securities are beneficially owned by the reporting person.

What role does the filer have at the issuer?

The reporting person is listed as a director of the issuer.

Was a Power of Attorney included with the filing?

Yes. The filing references Exhibit 24 — Power of Attorney and the form was signed by an attorney-in-fact.

Will this Form 3 trigger future Section 16 reports?

If the reporting person acquires or disposes of securities later, those transactions would require subsequent Section 16 reports (Forms 4 or 5). The current Form 3 reports no holdings today.